Trials / Terminated
TerminatedNCT04615845
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)
An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Pharmicell Co., Ltd. · Industry
- Sex
- Male
- Age
- 19 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells(DC) in patients with metastatic castration resistant prostate cancer (mCRPC)
Detailed description
To evaluate the safety of an autologous dendritic cell anticancer immune cell therapy (Cellgram-DC-PC) for the treatment of prostate cancer in patients with metastatic castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cellgram-DC-PC | Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes |
Timeline
- Start date
- 2021-06-21
- Primary completion
- 2022-02-15
- Completion
- 2022-02-15
- First posted
- 2020-11-04
- Last updated
- 2023-01-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04615845. Inclusion in this directory is not an endorsement.